$-0.90 EPS Expected for Merus N.V. (MRUS)

November 11, 2018 - By Michael Collier

Analysts expect Merus N.V. (NASDAQ:MRUS) to report $-0.90 EPS on November, 29.They anticipate $0.05 EPS change or 5.26 % from last quarter’s $-0.95 EPS. After having $-0.48 EPS previously, Merus N.V.’s analysts see 87.50 % EPS growth. The stock decreased 6.65% or $0.98 during the last trading session, reaching $13.75. About 16,769 shares traded. Merus N.V. (NASDAQ:MRUS) has risen 26.53% since November 11, 2017 and is uptrending. It has outperformed by 10.91% the S&P500.

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company has market cap of $311.20 million. The Company’s lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, gastric, and ovarian cancers. It currently has negative earnings. The firm also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies, as well as developing MCLA-158, a bispecific antibody candidate, which is designed to bind to cancer stem cells for the potential treatment of colorectal cancer.

More news for Merus N.V. (NASDAQ:MRUS) were recently published by: Benzinga.com, which released: “82 Biggest Movers From Yesterday” on November 01, 2018. Globenewswire.com‘s article titled: “Merus to Present at the Jefferies 2018 London Healthcare Conference” and published on November 08, 2018 is yet another important article.

Merus N.V. (NASDAQ:MRUS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.